Specific mutations in NOTCH1/2/4, TP53, and MYC, along with the activation of TGF-β receptor signaling pathways, may distinguish the clinical behavior of RDEB-cSCCs [11–13]. This evidence concerns the gene TP53 and recessive dystrophic epidermolysis bullosa.